This intelligence brief explores how agentic AI is transitioning from experimental discovery to large-scale operational deployment within the pharmaceutical industry. Highlighting latest trends in Biotech M&A, download covering the latest developments in AI and biotechnology, designed for pharma, biotech, and life sciences executives navigating the future of drug development, this Podcast aims at educating and entertaining by analyzing the most important news, breakthroughs, investments, M&A activity, and emerging technologies shaping the Biotech and Pharma industries. From AI-driven drug discovery and agentic systems to regulatory strategy, cell and gene therapy, and next-generation biotech platforms, this podcast goes beyond the headlines to transform complex developments into actionable strategic intelligence, identifying the signals that matter and revealing how they could shape the future of therapies, companies, and healthcare innovation. The Highlight of this week is 'A landmark agreement between Bristol Myers Squibb and Anthropic', that illustrates a shift toward using artificial intelligence to automate complex research, biomarker, regulatory, manufacturing, and clinical workflows. Beyond technology, the report analyzes shifting investment trends that favor de-risked assets, such as radiopharmaceuticals and clinical-stage Chinese innovations, over early-stage discovery. It also examines the evolving licensing landscape, where biological foundation models are now treated as essential infrastructure paid for with both capital and proprietary data. Furthermore, the sources discuss significant clinical milestones, including the FDA approval of advanced antibody-drug conjugates for first-line cancer treatment. Ultimately, the material provides a strategic framework for evaluating AI integration, emphasizing that the long-term value of these tools depends on their regulatory credibility and auditability.